At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Pre-Market Trading 12-20 07:08:38 EST
261.19
+2.41
+0.93%
盘前267.32
+6.13+2.35%
07:08 EST
High261.81Low253.30Vol4.73M
Open258.00D1 Closing258.78Amplitude3.29%
Mkt Cap140.40BTradable Cap140.04BTotal Shares537.53M
T/O1.23BT/O Rate0.88%Tradable Shares536.16M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
BUZZ-Weight-loss drug developers gain after Novo's obesity drug underperforms in study
Reuters  ·  28 minutes ago
BUZZ-Weight-loss drug developers gain after Novo's obesity drug underperforms in study
Amgen Shares up 5.3% Premarket After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected
THOMSON REUTERS  ·  40 minutes ago
Amgen Shares up 5.3% Premarket After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected
Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected
Reuters  ·  18:47
Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected
What is the Dow Jones Index and which 30 companies make the grade?
MotleyFool  ·  10:22
What is the Dow Jones Index and which 30 companies make the grade?
10 Biggest Losers of The Dow Jones Index's 10-Day Losing Streak
Blockhead  ·  04:59
10 Biggest Losers of The Dow Jones Index's 10-Day Losing Streak
Can Dow Jones ETF Reverse From the Worst Losing Streak in 50 Years?
Zacks  ·  02:00
Can Dow Jones ETF Reverse From the Worst Losing Streak in 50 Years?
Jefferies Adjusts Amgen Price Target to $350 From $380, Maintains Buy Rating
MT Newswires Live  ·  00:52
Jefferies Adjusts Amgen Price Target to $350 From $380, Maintains Buy Rating
Why Is Amgen Inc. (AMGN) Among the Best Dividend Stocks to Invest In?
Insider Monkey  ·  12-19 19:20
Why Is Amgen Inc. (AMGN) Among the Best Dividend Stocks to Invest In?
Amgen Inc. Stock Underperforms Wednesday When Compared To Competitors
Dow Jones  ·  12-19 05:39
Amgen Inc. Stock Underperforms Wednesday When Compared To Competitors
Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit
Reuters  ·  12-19 00:30
Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit
Amgen (AMGN) Stock Moves -0.21%: What You Should Know
Zacks  ·  12-18 06:50
Amgen (AMGN) Stock Moves -0.21%: What You Should Know
UBS Cuts Price Target on Amgen to $280 From $326, Maintains Neutral Rating
MT Newswires Live  ·  12-17 22:30
UBS Cuts Price Target on Amgen to $280 From $326, Maintains Neutral Rating
Is Amgen Inc. (AMGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Insider Monkey  ·  12-17
Is Amgen Inc. (AMGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Buy Rating for Veligrotug Driven by Positive Phase 3 Results and Competitive Edge Over Amgen’s Tepezza
TIPRANKS  ·  12-17
Buy Rating for Veligrotug Driven by Positive Phase 3 Results and Competitive Edge Over Amgen’s Tepezza
Amgen Inc. Stock Outperforms Competitors Despite Losses On The Day
Dow Jones  ·  12-17
Amgen Inc. Stock Outperforms Competitors Despite Losses On The Day
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
Blockhead  ·  12-16
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
Blockhead  ·  12-16
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
How Much Would It Take To Earn $100 A Month From Amgen Stock
Benzinga  ·  12-14
How Much Would It Take To Earn $100 A Month From Amgen Stock
Amgen Inc. Stock Underperforms Friday When Compared To Competitors
Dow Jones  ·  12-14
Amgen Inc. Stock Underperforms Friday When Compared To Competitors
Dow's 112-Point Fall Led By Losses In NVIDIA Corp., Amgen Shares
Dow Jones  ·  12-14
Dow's 112-Point Fall Led By Losses In NVIDIA Corp., Amgen Shares

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Issue price:
--